Targeting cancer with small molecule kinase inhibitors
Top Cited Papers
- 1 January 2009
- journal article
- review article
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 9 (1) , 28-39
- https://doi.org/10.1038/nrc2559
Abstract
Deregulation of kinase activity has emerged as a major mechanism by which cancer cells evade normal physiological constraints on growth and survival. To date, 11 kinase inhibitors have received US Food and Drug Administration approval as cancer treatments, and there are considerable efforts to develop selective small molecule inhibitors for a host of other kinases that are implicated in cancer and other diseases. Herein we discuss the current challenges in the field, such as designing selective inhibitors and developing strategies to overcome resistance mutations. This Review provides a broad overview of some of the approaches currently used to discover and characterize new kinase inhibitors.Keywords
This publication has 107 references indexed in Scilit:
- Identification of ALK as a major familial neuroblastoma predisposition geneNature, 2008
- Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesisNature, 2008
- Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitorsNature Biotechnology, 2007
- Patterns of somatic mutation in human cancer genomesNature, 2007
- Cell cycle kinases in cancerCurrent Opinion in Genetics & Development, 2007
- A clickable inhibitor reveals context-dependent autoactivation of p90 RSKNature Chemical Biology, 2007
- Current development of mTOR inhibitors as anticancer agentsNature Reviews Drug Discovery, 2006
- Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapyNature Clinical Practice Oncology, 2006
- A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin SignalingCell, 2006
- Mutations of the BRAF gene in human cancerNature, 2002